1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.2.1 MARKETS COVERED 17
1.2.2 YEARS CONSIDERED FOR THE STUDY 18
1.3 CURRENCY 18
1.4 LIMITATIONS 18
1.5 STAKEHOLDERS 19

2 RESEARCH METHODOLOGY 20
2.1 SECONDARY DATA 21
2.1.1 KEY DATA FROM SECONDARY SOURCES 21
2.2 PRIMARY DATA 22
2.2.1 KEY DATA FROM PRIMARY SOURCES 23
2.3 MARKET SIZE ESTIMATION 24
2.3.1 BOTTOM-UP APPROACH 24
2.3.2 TOP-DOWN APPROACH 25
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 26
2.5 ASSUMPTIONS FOR THE STUDY 27

3 EXECUTIVE SUMMARY 28

4 PREMIUM INSIGHTS 32
4.1 URINALYSIS: MARKET OVERVIEW 32
4.2 NORTH AMERICA: URINALYSIS MARKET, BY PRODUCT (2019) 33
4.3 GEOGRAPHICAL SNAPSHOT OF THE URINALYSIS MARKET 34

5 MARKET OVERVIEW 35
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 DRIVERS 36
5.2.1.1 Growing global prevalence of kidney diseases and urinary tract infections 36
5.2.1.2 Shift towards automation in sediment analysis 37
5.2.1.3 Increasing adoption of point-of-care urinalysis 37
5.2.2 OPPORTUNITIES 37
5.2.2.1 Integrated systems for urinalysis 37
5.2.2.2 Emerging economies 37
?
5.2.3 CHALLENGES 38
5.2.3.1 High cost of automated analyzers affecting market penetration in emerging economies 38

6 URINALYSIS MARKET, BY PRODUCT 39
6.1 INTRODUCTION 40
6.2 CONSUMABLES 41
6.2.1 PREGNANCY & FERTILITY KITS 42
6.2.1.1 Need for rapid pregnancy testing to drive market growth 42
6.2.2 DIPSTICKS 43
6.2.2.1 Dipsticks are used regularly due to their low cost and ease of use 43
6.2.3 DISPOSABLES 44
6.2.3.1 Wide usage of urine collection cups will drive the market for disposables 44
6.2.4 REAGENTS 44
6.2.4.1 Increasing use of controls and calibrators to drive market growth 44
6.3 INSTRUMENTS 45
6.3.1 AUTOMATED URINE ANALYZERS 46
6.3.1.1 Biochemical urine analyzers 47
6.3.1.1.1 Increasing incidence of kidney diseases and urinary tract infections will increase the demand for automated biochemical analyzers 47
6.3.1.2 Sediment urine analyzers 48
6.3.1.2.1 Microscopy analyzers 49
6.3.1.2.1.1 Increased adoption of automated microscopy analyzers to drive market growth 49
6.3.1.2.2 Flow cytometry analyzers 49
6.3.1.2.2.1 Accuracy and sensitivity of flow cytometry technique to drive the adoption of these analyzers 49
6.3.1.3 Integrated urine analyzers 50
6.3.1.3.1 Higher workload in hospitals and laboratories to drive the adoption of integrated systems 50
6.3.2 SEMI-AUTOMATED URINE ANALYZERS 51
6.3.2.1 Semi-automated urine analyzers are used extensively due to their low cost and ease of use 51
6.3.3 POINT-OF-CARE URINE ANALYZERS 51
6.3.3.1 Need for rapid testing to drive the demand for PoC devices 51
?

7 URINALYSIS MARKET, BY TEST TYPE 53
7.1 INTRODUCTION 54
7.2 PREGNANCY & FERTILITY TESTS 55
7.2.1 RISING INCIDENCE OF ACCIDENTAL PREGNANCIES TO DRIVE THE GROWTH OF THIS SEGMENT 55
7.3 BIOCHEMICAL URINALYSIS 55
7.3.1 LABORATORY TESTS 56
7.3.1.1 Increasing incidence of urinary tract infections and kidney diseases to drive the growth of this segment 56
7.3.2 POINT-OF-CARE TESTS 57
7.3.2.1 Ease and convenience of poc testing to drive the growth of this segment during the forecast period 57
7.4 SEDIMENT URINALYSIS 58
7.4.1 INCREASING ADOPTION OF AUTOMATED ANALYZERS TO DRIVE THE GROWTH OF THIS SEGMENT 58

8 URINALYSIS MARKET, BY APPLICATION 59
8.1 INTRODUCTION 60
8.2 DISEASE SCREENING 61
8.2.1 URINARY TRACT INFECTIONS 62
8.2.1.1 Increasing prevalence of UTIs to drive growth in the urinalysis market for disease screening 62
8.2.2 KIDNEY DISEASES 62
8.2.2.1 Rapidly growing global geriatric population and the subsequent increase in the prevalence of kidney diseases to drive market growth 62
8.2.3 DIABETES 63
8.2.3.1 Development of advanced analytical tools for diabetes will drive market growth 63
8.2.4 LIVER DISEASES 64
8.2.4.1 High prevalence of liver diseases will increase the demand for urinalysis 64
8.2.5 OTHER DISEASE SCREENING APPLICATIONS 65
8.3 PREGNANCY & FERTILITY 65
8.3.1 NEED FOR EARLY DETECTION OF PREGNANCY & FERTILITY TO DRIVE GROWTH IN THE URINALYSIS MARKET 65

9 URINALYSIS MARKET, BY END USER 67
9.1 INTRODUCTION 68
9.2 HOSPITALS & CLINICS 70
9.2.1 INCREASE IN HOSPITALIZATIONS FOR URINARY DISEASES TO DRIVE GROWTH IN THIS END-USER SEGMENT 70
9.3 DIAGNOSTIC LABORATORIES 71
9.3.1 LARGE NUMBER OF DIAGNOSTIC LABORATORIES CARRYING OUT TESTS GLOBALLY TO DRIVE MARKET GROWTH 71
?
9.4 HOME CARE SETTINGS 72
9.4.1 WIDESPREAD USE OF PREGNANCY KITS IN HOME CARE SETTINGS TO DRIVE MARKET GROWTH 72
9.5 RESEARCH LABORATORIES & INSTITUTES 73
9.5.1 RESEARCH IN DEVELOPING NEW URINALYSIS KITS FOR DISEASE DIAGNOSIS WILL DRIVE MARKET GROWTH 73

10 URINALYSIS MARKET, BY REGION 74
10.1 INTRODUCTION 75
10.2 NORTH AMERICA 76
10.2.1 US 80
10.2.1.1 US dominates the North American urinalysis market 80
10.2.2 CANADA 82
10.2.2.1 Increasing awareness about UTIs will drive market growth in Canada 82
10.3 EUROPE 84
10.3.1 GERMANY 87
10.3.1.1 Germany dominates the European urinalysis market 87
10.3.2 UK 89
10.3.2.1 UK to register the highest growth in the European market during the forecast period 89
10.3.3 FRANCE 90
10.3.3.1 Favorable demographics will support the adoption of urinalysis equipment in France 90
10.3.4 ITALY 92
10.3.4.1 Large geriatric population to drive the growth of the urinalysis market in Italy 92
10.3.5 SPAIN 94
10.3.5.1 Prevalence of CKD in Spain to drive the demand for urinalysis 94
10.3.6 REST OF EUROPE 95
10.4 ASIA PACIFIC 97
10.4.1 CHINA 101
10.4.1.1 China accounts for the largest share of the APAC market 101
10.4.2 JAPAN 103
10.4.2.1 Well-developed healthcare system and universal healthcare reimbursement policy will ensure steady market growth 103
10.4.3 INDIA 104
10.4.3.1 Increasing incidence of CKD is driving market growth 104
10.4.4 REST OF APAC 106
10.5 REST OF THE WORLD 108
?

11 COMPETITIVE LANDSCAPE 111
11.1 OVERVIEW 111
11.2 MARKET RANKING ANALYSIS, 2018 111
11.3 KEY STRATEGIES 114
11.3.1 PRODUCT LAUNCHES, 2016–2018 114
11.3.2 EXPANSIONS, 2016–2018 114
11.3.3 PARTNERSHIPS, 2016–2018 114
11.4 COMPETITIVE LEADERSHIP MAPPING (2018) 115
11.4.1 VENDOR INCLUSION CRITERIA 115
11.4.2 VISIONARY LEADERS 115
11.4.3 INNOVATORS 115
11.4.4 DYNAMIC DIFFERENTIATORS 115
11.4.5 EMERGING COMPANIES 115
11.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2018) 116
11.5.1 PROGRESSIVE COMPANIES 116
11.5.2 STARTING BLOCKS 117
11.5.3 RESPONSIVE COMPANIES 117
11.5.4 DYNAMIC COMPANIES 117
12 COMPANY PROFILES 118
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 CARDINAL HEALTH, INC. 118
12.2 ALERE, INC. (A PART OF ABBOTT LABORATORIES) 120
12.3 SIEMENS HEALTHINEERS 122
12.4 ROCHE DIAGNOSTICS 124
12.5 BECKMAN COULTER INC. (SUBSIDIARY OF DANAHER CORPORATION) 126
12.6 SYSMEX CORPORATION 128
12.7 QUIDEL CORPORATION 130
12.8 BIO-RAD LABORATORIES, INC. 132
12.9 ARKRAY, INC. 134
12.10 ACON LABORATORIES, INC. 135
12.11 77 ELEKTRONIKA KFT 137
12.12 URIT MEDICAL ELECTRONIC GROUP CO., LTD. 138
12.13 DIRUI INDUSTRIAL CO., LTD. 139

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
?
13 APPENDIX 140
13.1 INSIGHTS OF INDUSTRY EXPERTS 140
13.2 DISCUSSION GUIDE 141
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS? SUBSCRIPTION PORTAL 143
13.4 AVAILABLE CUSTOMIZATIONS 145
13.5 RELATED REPORTS 145
13.6 AUTHOR DETAILS 146